Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Article Page

Keywords: IPSS, primary myelofibrosis, ruxolitinib.

Citation: Accurso V, Santoro M, Mancuso S, Napolitano M, Di Piazza F, Russo A, Siragusa SM. Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. Drugs in Context 2019; 8: 212569. DOI: 10.7573/dic.212569

Contributions: All authors followed the patient and critically contributed to manuscript drafting. All authors have read and approved the final version of the paper. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2019/02/dic.212569-COI.pdf

Acknowledgements: Editorial assistance for the preparation of this manuscript was performed by Luca Giacomelli PhD and Aashni Shah (Polistudium, Milan, Italy) on behalf of Content Ed Net (Rome, Italy).

Funding declaration: Medical writing assistance was funded by Novartis Farma.

Copyright: Copyright © 2019 Accurso V, Santoro M, Mancuso S, Napolitano M, Di Piazza F, Russo A, Siragusa SM. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Accurso V, Santoro M, Mancuso S, Napolitano M, Di Piazza F, Russo A, Siragusa SM. https://doi.org/10.7573/dic.212569. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/efficacy-of-ruxolitinib-retreatment-in-a-patient-with-high-risk-myelofibrosis-using-the-international-prognostic-scoring-system

Correspondence: Vincenzo Accurso, Divisione di Ematologia A.O.U.P. Palermo, Palermo, Italy. casteldaccia@tiscali.it

Provenance: submitted; externally peer reviewed.

Submitted: 1 November 2018; Peer review comments to author: 28 November 2018; Revised manuscript received: 31 January 2019; Accepted: 1 February 2019; Publication date: 4 March 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF